{"entity":{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","aka":[],"tldr":"A phase 3 trial of Pasireotide and Somatostatin analogues in Pituitary tumours, run by Novartis Pharmaceuticals, completed.","summary":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly is a phase 3 interventional study registered as NCT00600886 by Novartis Pharmaceuticals, with 358 participants recorded, started 2008-02-11 and reaching its primary completion in 2016-03-11. Interventions recorded: Pasireotide, Octreotide. Conditions recorded: Acromegaly.\n\nLinked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00600886","url":"https://clinicaltrials.gov/study/NCT00600886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["pasireotide","octreotide-lanreotide"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00600886","phase":"3","setting":"A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT00600886","source":"https://clinicaltrials.gov/study/NCT00600886","fetchedAt":"2026-10-07T16:52:09.625Z","studySha256":"ecfd63ed247c8ceb3da436b88f88b86278a17652166da21eb701b36c3f11139a","overallStatus":"COMPLETED","lastUpdatePosted":"2017-07-02","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":358,"enrolmentType":"ACTUAL","siteCount":95,"recruitingSiteCount":0,"countries":["Argentina","Belgium","Brazil","Canada","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Mexico","Netherlands","Norway","Poland","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2008-02-11","startedType":"actual","yearReported":2015,"enrolled":358,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1, Overall","primary":true,"unit":"%","arms":[{"name":"Pasireotide LAR (Core)","n":176,"value":31.3,"note":"95% CI 24.5 to 38.7; Figures from the ClinicalTrials.gov results section (first posted 2015-01-30), not from a publication"},{"name":"Octreotide LAR (Core)","n":182,"value":19.2,"note":"95% CI 13.8 to 25.7"}],"p":"0.007","source":"https://clinicaltrials.gov/study/NCT00600886?tab=results"}]},"route":"/trials/nct00600886/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/"},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}